Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine ophthalmic solution 0.6% in pediatric allergic conjunctivitis
2020-002098-86Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing Bilastine ophthalmic solution 0.6% with Placebo ophthalmic solution (2 arms). Primary endpoint: Incidence of related ocular treatment-emergent adverse events. Started Feb 2021; status: completed.
02
Drugs
bilastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2020-002098-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002098-86.